



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/920,517	08/01/2001	Michael F. Clarke	060173-0014 (UMIP-003)	6988

7590 01/24/2005

MEDLEN & CARROLL, LLP
101 Howard Street
Suite 305
San Francisco, CA 94105

EXAMINER

LI, QIAN JANICE

ART UNIT	PAPER NUMBER
----------	--------------

1632

DATE MAILED: 01/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/920, 5.7	8/1/01	Clarke, M	060173-0014

EXAMINER	
G. Janice Li	
ART UNIT	PAPER NUMBER
1632	

DATE MAILED:

EXAMINER INTERVIEW SUMMARY RECORD

All participants (applicant, applicant's representative, PTO personnel):

- (1) Giam Janice Li PRO (3) M. Clarke, Inventor,
(2) David Casimir, Appl. Rep. (4) M. H. Goldstein, Chained Rep-

Date of interview _____

Type: ☐ Telephonic ☐ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☐ Yes ☐ No. If yes, brief description: _____

Agreement ☐ was reached with respect to some or all of the claims in question. ☐ was not reached.

Claims discussed: _____

Identification of prior art discussed: _____

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: _____

Continued. of 0024¹¹⁰, the product claims would allowable. Based on the proposed amendment, the method claims would be allowable. Dr. Clarke gave a in-depth slide-show concerning the biology of tumor stem cells. Applicants agreed to add the limitation of 0024 when submitting a formal response.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

- ☐ 1. It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph below has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW (e.g., items 1-7 on the reverse side of this form). If a response to the last Office action has already been filed, then applicant is given one month from this interview date to provide a statement of the substance of the interview.

- ☐ 2. Since the examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the substance of the interview unless box 1 above is also checked.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/920,517	8/1/01	Clarke, M	06 0173-0014

EXAMINER	
G. Janice Li	
ART UNIT	PAPER NUMBER
1632	

DATE MAILED:

EXAMINER INTERVIEW SUMMARY RECORD

All participants (applicant, applicant's representative, PTO personnel):

- (1) G. Janice Li, PTO (3) M. Clarke, Inventor,
(2) David Casimir, Appl. Rep (4) M.H. Goldstein, Assignee rep.

Date of interview 1/13/05

Type: ☐ Telephonic ☒ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☒ Yes ☐ No. If yes, brief description: draft amends & response.

Agreement ☐ was reached with respect to some or all of the claims in question. ☐ was not reached.

N/A

Claims discussed: All pending.

Identification of prior art discussed: Cited art of record.

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: The Examiner pointed out that all product claims except claims 206-209 are subject to new matter & enablement rej. because deleting CD24 marker is a departure from the original disclosure showing only CD24⁺ are stem cells, amends encompass CD24⁺, which was taught by specification as non-tumor stem cell population. But if amend the product claims to add the limitation

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

☐ 1. It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph below has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW (e.g., items 1-7 on the reverse side of this form). If a response to the last Office action has already been filed, then applicant is given one month from this interview date to provide a statement of the substance of the interview.

☐ 2. Since the examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the substance of the interview unless box 1 above is also checked.